A Real World Study Evaluating the Long-Term Quality of Life of Tildrakizumab in Adult Patients With Psoriasis
Status:
Recruiting
Trial end date:
2027-12-31
Target enrollment:
Participant gender:
Summary
This is a Phase 4 multicenter, uncontrolled open-label study design. There will be a total of
10 study visits at Screening, Baseline, Week 4, Week 8, Week 12, Week 16, Week 28, Week 40,
Week 52 and Week 64, with subjects receiving tildrakizumab injections at Week 0, Week 4, Week
16, Week 28, Week 40, and Week 52. The total study duration will be approximately 64 weeks,
excluding a screening period.
Phase:
Phase 4
Details
Lead Sponsor:
Sun Pharma Global FZE Sun Pharmaceutical Industries Limited